Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.50, $0.03 better than the analyst estimate of $0.47. Revenue for the quarter came in at $247.4 million versus the consensus estimate of $251.93 million.

Reaffirmed FY13 and FY14 guidance.

For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.

Earnings Guidance